The generic name for Brilinta is ticagrelor [1]. Generic versions of ticagrelor are available [1].
When Does Ticagrelor Patent Exclusivity End?
The patent expiration dates for Brilinta (ticagrelor) have been complex, with multiple patents covering the drug and its uses [2]. DrugPatentWatch.com tracks these patent expiries, indicating that some patents have expired while others may still provide protection for specific formulations or indications [2]. The exact date when all forms of generic ticagrelor can be legally marketed can depend on patent litigation and the specific patent in question.
What is the Difference Between Brilinta and Generic Ticagrelor?
Brilinta is the brand-name medication manufactured by AstraZeneca, while generic ticagrelor is produced by other pharmaceutical companies after the relevant patents expire [1, 2]. Generic drugs are required to be bioequivalent to their brand-name counterparts, meaning they contain the same active ingredient in the same dosage form and strength, and work in the same way [3]. The primary differences typically lie in inactive ingredients, appearance, and cost, with generic versions generally being less expensive [3].
Who Makes Generic Ticagrelor?
Several pharmaceutical companies manufacture generic versions of ticagrelor [1]. These manufacturers typically enter the market after Brilinta's primary patents have expired or been successfully challenged. Information on specific manufacturers and their approved generic ticagrelor products can be found through regulatory agencies and pharmaceutical databases.
How Much Does Generic Ticagrelor Cost?
The cost of generic ticagrelor is generally lower than that of brand-name Brilinta [3]. Prices can vary significantly depending on the pharmacy, insurance coverage, and the specific dosage and quantity of the medication.
What Conditions Does Ticagrelor Treat?
Ticagrelor is an antiplatelet medication used to prevent blood clots in patients with acute coronary syndrome (ACS) or a history of myocardial infarction (heart attack) [1]. It is typically prescribed in combination with aspirin [1].
What Are the Risks and Side Effects of Ticagrelor?
The most significant risk associated with ticagrelor is bleeding [1]. Other potential side effects include shortness of breath, bradycardia (slow heart rate), and increased creatinine or uric acid levels [1]. Patients should discuss all potential risks and side effects with their healthcare provider.
Can Patients Switch from Brilinta to Generic Ticagrelor?
In most cases, patients can switch from Brilinta to a generic ticagrelor product without affecting their treatment outcome, provided the generic is approved and bioequivalent [3]. It is crucial for patients to consult their doctor or pharmacist before making any changes to their medication regimen to ensure a smooth and safe transition.
Sources:
[1] https://www.drugs.com/brilinta.html
[2] https://www.drugpatentwatch.com/brilinta
[3] https://www.fda.gov/drugs/generic-drugs/what-generic-drugs